Premium
Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2‐year follow‐up report of a national, prospective prostatic cancer study
Author(s) -
Arto Mikkola,
Mirja Ruutu,
Jussi Aro,
S. Rannikko,
J. Salo
Publication year - 1998
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1046/j.1464-410x.1998.00688.x
Subject(s) - medicine , prostate cancer , cancer , prospective cohort study , prostate , thrombosis , surgery , myocardial infarction , group b , urology , gastroenterology
Objective To evaluate the clinical efficacy and cardiovascular complications of orchidectomy or polyoestradiol phosphate (PEP) in the treatment of advanced prostatic cancer. Patients and methods In a prospective, randomized study 444 patients (mean age 73 years, range 45–91) with T3–4 M0 or T1–4 M1 prostatic cancer were treated either by orchidectomy (group 1, n =217) or parenteral PEP (group 2, n =227; 240 mg/month). The patients were examined at 3 and 6 months after start of the therapy and thereafter every 6 months; they were also assessed whenever they had symptoms indicating progression. Possible cardiovascular complications included myocardial infarction, cerebrovascular accident, pulmonary embolism and deep vein thrombosis. Results After a follow‐up of 2 years there was no statistically significant difference between the groups in progression‐free time; 65 of 217 (30%) patients in group 1 showed evidence of progression, including seven (3%) who died from prostate cancer. In group 2, 64 of 227 (28%) patients showed progression and eight (3.5%) died from prostatic cancer. There were 10 (5%) cardiovascular complications in patients in group 1, including five (2%) cardiovascular deaths; in group 2 there were 24 (11%) and 14 (6%), respectively. During the first year of treatment there were three (1.4%) cardiovascular complications in group 1 and 14 (6%) in group 2 ( P <0.05), and during the second year, seven (4%) and 10 (6%), respectively. Conclusion Parenteral PEP (240 mg/month) seems to be as efficient as orchidectomy in inhibiting disease in patients with advanced prostatic cancer (T3–4 M0 and T1–4 M1). There were more cardiovascular complications in patients treated with PEP than after orchidectomy; the difference was statistically significant during the first year of treatment.